Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.
Nicolaus Kröger, MD
Advertisement
Articles by Nicolaus Kröger, MD
Nicolaus Kröger, MD, discusses the role of allogenic stem cell transplant in patients with multiple myeloma.
Nicolaus Kröger, MD, discusses the long-term results of a phase 2 study in multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Kröger on Toxicities Associated With Allogeneic Stem Cell Transplant in MyelomaPublished: May 11th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
5